NCT06819735View on ClinicalTrials.gov

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

January 31, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

DT-7012

Intravenous infusion

DRUG

Immune checkpoint inhibitor

Intravenous infusion

Trial Locations (5)

2109

RECRUITING

Macquarie University Clinical Trial Unit, North Ryde

3144

RECRUITING

Cabrini Health Limited, Malvern

3199

RECRUITING

Peninsula & South Eastern Haematology & Oncology Group, Frankston

5000

RECRUITING

Cancer Research SA, Adelaide

6009

RECRUITING

One Clinical Research Pty Ltd, Nedlands

Sponsors

Collaborators (1)

Domain Therapeutics SA
All Listed Sponsors
collaborator

Domain Therapeutics SA

INDUSTRY

lead

Domain Therapeutics Australia Pty Ltd

INDUSTRY